Tagged with M&A

Pharma The CEO of Onxeo, recently formed through the merger of the French BioAlliance Pharma and the Danish Topotarget, discusses its strategic turning decision to focus on orphan oncology, its promising pipeline of innovative products, her “positively opportunistic” attitude towards partnerships and international expansion, and the company’s overall strategy for differentiating…

Pharma Alessandra Modenese Kauffmann, General Manager of the Swiss Chamber of Commerce, shares her insights into the relationship between Italy and Switzerland, the Chamber’s efforts to foster trade between the two countries and the opportunities offered through close collaboration between Swiss and Italian companies. Alessandra, the chamber has been active in…

Pharma Mr. Michel Finance, CEO of Theradiag, a leading French player in in vitro diagnostics and the novel field of theranostics (a combination of treatment and diagnosis), discusses the major restructuring at Theradiag he oversaw, the crucial role that diagnostics play in the provision of efficient as well as cost-effective healthcare…

Pharma After a successful IPO on Nasdaq in May 2015, Galapagos is ready to continue developing its robust portfolio of clinical-stage breakthrough therapies with the potential to revolutionize existing treatment paradigms. The CEO discusses his current priorities as well as his vision to transform Galapagos into a specialty pharmaceutical company. In…

Pharma The CSO and COO of BioNovion talk about the company’s recent acquisition by US-based biotech Aduro. BioNovion is a Dutch biopharma specialized in immune oncology antibody discovery. Immunotherapy has become a clinical reality as an effective approach to treat advanced cancer and BioNovion plans to keep leveraging the fruitful collaboration with top-notch research centers…

Pharma The President of Innothera talks about their unique business model, being in both the drug production and compression stockings businesses, how almost 95 percent of their drug production is exported, primarily to emerging countries, and why there is a very hopeful future for medium-sized companies that are ready to embrace…

Pharma Muhammad Bodhania, Managing Director of Medreich South Africa discusses potential strategic implications of the recent acquisition of Medreich by Meiji and the importance of local partnerships for global success. Can you please give an overview of Medreich’s activites in South Africa, and how the Meiji acquisition has affected the company’s strategic outlook? The…

Mylan The general manager of one of the world’s largest API manufacturers recalls the recent acquisition of Abbott by Mylan and the processes which he has undertaken to set his entity off along a new path. He also elaborates on the band consciousness of the Romanian consumer and how that affects…

distribution José Antonio Crespo became general manager for Beckman Coulter Iberia in July 2013, following an extensive career at Siemens. He discusses the structural changes associated with the company’s acquisition by Danaher, and outlines targets for growth in the coming years.   What initial challenges did you face at the beginning…

women's health Leandro Sigman, general manager of Chemo, discusses changes in the Spanish market and the company’s strategy to target international markets.   The crisis has changed the way companies operate in Spain, but Chemo has continued to succeed. What have been some of the key strategies employed? It has been a…

mergers The global pharmaceutical sector continues to witness significant mergers and acquisitions activity, with 122 M&A deals completed in 2013. This trend has continued due to several multi-billion dollar deals around the world in 2014, which is already recorded the busiest year for healthcare acquisitions. In Chile, the dealmaking sweeping started in December 2013…